Which breathing aid keeps patients off the ventilator longer?

NCT ID NCT06918288

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This trial compares two types of breathing support given right after a breathing tube is removed in patients over 50 with type II respiratory failure who had difficulty weaning from a ventilator. One method delivers warm, moist oxygen through small nasal prongs, while the other uses a mask to provide positive-pressure support. The goal is to see which approach better prevents the need for reintubation within 72 hours and 7 days after extubation.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
High-Flow Nasal Cannula (HFNC) and Non-Invasive Ventilation (NIV) devices
What this could lead to
If one approach proves better, it could reduce the need for reintubation and improve recovery in patients with type II respiratory failure after breathing-tube removal.
What could go wrong
This is a single-center trial, and results may not apply to all patients. Both devices have limitations, and individual responses can vary, so neither may clearly outperform the other.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

200 people

The number who actually took part.

Started

Apr 2025

Finished

Nov 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

51 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age \>50 years. * Type II respiratory failure. * Receiving invasive mechanical ventilation. * Difficult weaning from invasive mechanical ventilation, defined as failure to wean after 3-7 days of weaning attempts. * Fulfillment of predefined clinical criteria for extubation. * Written informed consent. Exclusion Criteria: * Refusal to participate or absence of informed consent. * Contraindication to NIV, including hemodynamic instability, excessive respiratory secretions with poor expectoration ability, oral or facial trauma, or recent esophageal surgery. * Poor short-term prognosis, including a very high risk of death within 7 days or receipt of palliative care. * Severe failure of another organ system, including severe cardiac, neurological, renal, or hepatic failure. * Existing tracheostomy. * Loss to follow-up resulting in uncertain 28-day survival.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hypercapnic respiratory failure are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Hypercapnia Hypoventilation respiratory failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Benha University Hospital

    Banhā, Qalyubia Governorate, 13511, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.